IPH Stock Overview
A biotechnology company, develops immunotherapies for cancer patients in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Innate Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.50 |
| 52 Week High | €2.80 |
| 52 Week Low | €1.40 |
| Beta | 0.87 |
| 11 Month Change | -19.68% |
| 3 Month Change | -27.09% |
| 1 Year Change | -35.95% |
| 33 Year Change | -64.96% |
| 5 Year Change | -72.29% |
| Change since IPO | -68.90% |
Recent News & Updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)
Oct 24
Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
May 21Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 24Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Dec 21Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Sep 30Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Sep 16Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Jun 09News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Mar 30Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic
Dec 18Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?
Sep 27Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year
Aug 04Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts
May 12Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts
Apr 13Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook
Mar 26Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?
Nov 11Shareholder Returns
| IPH | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -9.4% | -6.9% | -1.7% |
| 1Y | -35.9% | -27.3% | -1.9% |
Return vs Industry: IPH underperformed the French Biotechs industry which returned -27.3% over the past year.
Return vs Market: IPH underperformed the French Market which returned -1.9% over the past year.
Price Volatility
| IPH volatility | |
|---|---|
| IPH Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.4% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: IPH has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: IPH's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 168 | Jonathan Dickinson | www.innate-pharma.com |
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
Innate Pharma S.A. Fundamentals Summary
| IPH fundamental statistics | |
|---|---|
| Market cap | €116.57m |
| Earnings (TTM) | -€34.05m |
| Revenue (TTM) | €33.79m |
3.6x
P/S Ratio-3.6x
P/E RatioIs IPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPH income statement (TTM) | |
|---|---|
| Revenue | €33.79m |
| Cost of Revenue | €53.65m |
| Gross Profit | -€19.86m |
| Other Expenses | €14.20m |
| Earnings | -€34.05m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | -58.77% |
| Net Profit Margin | -100.78% |
| Debt/Equity Ratio | 121.3% |
How did IPH perform over the long term?
See historical performance and comparison